Immunitybio reports sales momentum & unit growth since permanent j-code issuance (j9028) in january 2025 and financial results for year end 2024

Culver city, calif.--(business wire)--immunitybio, inc. (nasdaq: ibrx), a leading immunotherapy company, today announced certain operational results following approval of the permanent j-code (j9028) in january 2025, as well as its financial results for the fourth-quarter and full year ended december 31, 2024. with the issuance of the permanent j-code in january 2025, immunitybio has seen increased sales momentum supporting a trend of increases month-over-month as well as quarter-over-quarter,.
IBRX Ratings Summary
IBRX Quant Ranking